MeiraGTx Holdings plc MGTX

MGTX Company Overview

MeiraGTx Holdings plc is a clinical-stage genetic medicines company focused on developing and commercializing gene therapies for inherited and acquired diseases. The company operates primarily in the biotechnology and advanced therapeutics industries, with a concentration on adeno-associated virus (AAV)-based gene therapies, cell engineering technologies, and gene regulation platforms. MeiraGTx develops therapies targeting ophthalmology, neurodegenerative diseases, xerostomia, and other severe conditions with significant unmet medical needs. Its revenue historically has been derived primarily from collaboration agreements, licensing arrangements, and research funding rather than commercial product sales, as the company remains in the clinical development stage.

The company was founded in 2015 through the consolidation of several gene therapy programs and manufacturing capabilities in the United Kingdom and the United States. MeiraGTx has differentiated itself through its vertically integrated manufacturing strategy, proprietary viral vector production capabilities, and regulated gene expression technology platform. The company has emphasized control over manufacturing quality and scalability through ownership of specialized production infrastructure, positioning itself as both a therapy developer and advanced genetic medicine manufacturer.